cabozantinib,atezolizumab
exelixis,roche
['atezolizumab', 'sclc', 'nsclc', 'cabozantinib']
cosmic-21 cabozatinib+atezolizumab or cabozantinib in advanced nsclc previously treated with ici by cabozantinib plus atezolizumab showed clinical activity
orr=19%
mpfs=4.5 mo
mos=13.8 mo there are several ongoing trials testing cabozantinib + ici in nsclc #asco22 
Oncologist taking care of people with cancer at Georgetown University | Father/husband/immigrant | #SoMeEditor @ClinicalLung | #LCSM